Atreca (BCEL) Stock Forecast, Price Target & Predictions
BCEL Stock Forecast
Atreca stock forecast is as follows: an average price target of $4.00 (represents a 4344.44% upside from BCEL’s last price of $0.09) and a rating consensus of 'Buy', based on 1 wall street analysts offering a 1-year stock forecast.
BCEL Price Target
BCEL Analyst Ratings
Buy
Atreca Price Target by Analyst
Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
---|---|---|---|---|---|---|
Nov 15, 2022 | - | Wedbush | $4.00 | $1.48 | 171.19% | 4344.44% |
10
Atreca Price Target by Period
1M | 3M | 12M | |
---|---|---|---|
# Anlaysts | - | - | - |
Avg Price Target | - | - | - |
Last Closing Price | $0.09 | $0.09 | $0.09 |
Upside/Downside | -100.00% | -100.00% | -100.00% |
Analyst Ratings Upgrades/Downgrades
Date | Company | Previous Rating | New Rating | Rating Change |
---|---|---|---|---|
Nov 15, 2022 | Wedbush | Outperform | Outperform | Hold |
10
Atreca Financial Forecast
Atreca Revenue Forecast
Quarter
Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Dec 20 | |
---|---|---|---|---|---|---|---|
Revenue | - | - | - | - | - | - | - |
Avg Forecast | $59.77K | $63.36K | $67.16K | $71.19K | $75.47K | $80.00K | $216.67K |
High Forecast | $59.77K | $63.36K | $67.16K | $71.19K | $75.47K | $80.00K | $216.67K |
Low Forecast | $59.77K | $63.36K | $67.16K | $71.19K | $75.47K | $80.00K | $216.67K |
# Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
Surprise % | - | - | - | - | - | - | - |
Forecast
Atreca EBITDA Forecast
Quarter
Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Dec 20 | |
---|---|---|---|---|---|---|---|
# Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
EBITDA | - | - | - | - | - | - | $-22.43M |
Avg Forecast | $-35.86K | $-38.01K | $-40.30K | $-42.72K | $-45.28K | $-48.00K | $-130.00K |
High Forecast | $-35.86K | $-38.01K | $-40.30K | $-42.72K | $-45.28K | $-48.00K | $-130.00K |
Low Forecast | $-35.86K | $-38.01K | $-40.30K | $-42.72K | $-45.28K | $-48.00K | $-130.00K |
Surprise % | - | - | - | - | - | - | 172.57% |
Forecast
Atreca Net Income Forecast
Quarter
Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Dec 20 | |
---|---|---|---|---|---|---|---|
# Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
Net Income | - | - | - | - | - | - | $-23.01M |
Avg Forecast | $-9.44M | $-8.23M | $-8.62M | $-10.41M | $-13.77M | $-14.79M | $-25.46M |
High Forecast | $-9.44M | $-8.23M | $-8.62M | $-10.41M | $-13.22M | $-14.79M | $-25.46M |
Low Forecast | $-9.44M | $-8.23M | $-8.62M | $-10.41M | $-13.77M | $-14.79M | $-25.46M |
Surprise % | - | - | - | - | - | - | 0.90% |
Forecast
Atreca SG&A Forecast
Quarter
Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Dec 20 | |
---|---|---|---|---|---|---|---|
# Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
SG&A | - | - | - | - | - | - | $6.64M |
Avg Forecast | $1.29M | $1.36M | $1.45M | $1.53M | $1.62M | $1.72M | $4.66M |
High Forecast | $1.29M | $1.36M | $1.45M | $1.53M | $1.62M | $1.72M | $4.66M |
Low Forecast | $1.29M | $1.36M | $1.45M | $1.53M | $1.62M | $1.72M | $4.66M |
Surprise % | - | - | - | - | - | - | 1.42% |
Forecast
Atreca EPS Forecast
Quarter
Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Dec 20 | |
---|---|---|---|---|---|---|---|
# Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
EPS | - | - | - | - | - | - | $-0.62 |
Avg Forecast | $-0.24 | $-0.21 | $-0.22 | $-0.26 | $-0.35 | $-0.38 | $-0.65 |
High Forecast | $-0.24 | $-0.21 | $-0.22 | $-0.26 | $-0.34 | $-0.38 | $-0.65 |
Low Forecast | $-0.24 | $-0.21 | $-0.22 | $-0.26 | $-0.35 | $-0.38 | $-0.65 |
Surprise % | - | - | - | - | - | - | 0.97% |
Forecast
Atreca Peer Comparison by Price Target
Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
---|---|---|---|---|---|
BCEL | Atreca | $0.09 | $4.00 | 4344.44% | Buy |
PASG | Passage Bio | $0.51 | $6.00 | 1076.47% | Buy |
BDTX | Black Diamond Therapeutics | $2.43 | $14.75 | 507.00% | Buy |
FIXX | Q32 Bio | $0.93 | $2.70 | 190.32% | Buy |
STOK | Stoke Therapeutics | $11.31 | $30.60 | 170.56% | Buy |
ALEC | Alector | $3.64 | $4.00 | 9.89% | Buy |
RVMD | Revolution Medicines, Inc. Warrant | $57.07 | $60.63 | 6.24% | Buy |